Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (18)

2023

  1. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

    Cancers, Vol. 15, Núm. 12

2022

  1. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

  2. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  2. Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens

    Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480

  3. Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients

    Journal of Clinical Medicine, Vol. 8, Núm. 12

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653

  2. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

2009

  1. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

2008

  1. Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens

    BMC Molecular Biology, Vol. 9

  2. Identification of VEGF-regulated genes associated with increased lung metastatic potential: Functional involvement of tenascin-C in tumor growth and lung metastasis

    Oncogene, Vol. 27, Núm. 40, pp. 5373-5384

2001

  1. Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

    Cardiovascular Research, Vol. 49, Núm. 2, pp. 484-492

2000

  1. Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis

    Hepatology, Vol. 31, Núm. 3, pp. 592-600

  2. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1

    Thrombosis and Haemostasis, Vol. 84, Núm. 1, pp. 65-70